Open AccessLow Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
Author(s) -
He-Jiun Jiang,
YenHsiang Chang,
YenHao Chen,
CheWei Wu,
PeiWen Wang,
PiJung Hsiao
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s326255
Subject(s) - lenvatinib , medicine , discontinuation , tolerability , adverse effect , refractory (planetary science) , thyroid carcinoma , gastroenterology , oncology , thyroid , thyroid cancer , urology , physics , astrobiology
Lenvatinib treatment of 24 mg/day for radioiodine-refractory differentiated thyroid carcinoma (RRDTC) patients was almost intolerable, with high rates of dose reduction, interruption and discontinuation. Balancing treatment safety with disease risks remains challenging, and the appropriate dosage remains unclear in Asia.